Ticker

ROCKVILLE, Md., March 31, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, reported today that Compensation Committee of the Board of Directors of MaxCyte granted inducement awards in the form of stock options to purchase an…

MaxCyte (NASDAQ: MXCT) executives told investors the company made "meaningful progress" in 2025 despite a difficult operating environment, highlighting continued strategic platform license (SPL) activity, integration of the SeQure Dx acquisition, cost restructuring, and the February launch of a new research-focused electroporation system. Management also provided 2026 revenue guidance that reflects ongoing headwinds…

MaxCyte, Inc. (MXCT) Q4 2025 Earnings Call Transcript

MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.1 per share a year ago.

Fourth quarter 2025 total revenue of $7.3 million at the top of the range of previous preliminary announcement Full year 2025 revenue of $33.0 million, at the top of the range of previous preliminary announcement Total cash, cash equivalents and investments were $155.6 million as of December 31, 2025. Expects to end 2026 with at least $136 million in t otal cash, cash equivalents and investments Expects 2026 revenue…